Last updated: February 14, 2026
Overview of the Product
NDC 00074-3641 corresponds to a generic formulation of dasatinib, a tyrosine kinase inhibitor primarily used in the treatment of chronic myeloid leukemia (CML). This drug competes with branded formulations like Bristol-Myers Squibb’s Sprycel. Generic approval by the FDA indicates market entry potential for multiple manufacturers, affecting pricing, demand, and competitive dynamics.
Market Size and Demand
The global CML market is valued at approximately USD 1.3 billion in 2022. The treatment landscape sees a high penetration of tyrosine kinase inhibitors (TKIs), with dasatinib accounting for roughly 20-25% of this market segment. Key factors influencing demand include:
- Incidence of CML, estimated at 1-2 cases per 100,000 worldwide.
- Treatment duration, often lifelong, creating stable demand.
- Shifts toward generic options reducing costs for payers and increasing patient access.
In 2022, the US accounts for nearly 40% of the global market, with the rest distributed among Europe, Asia-Pacific, and other regions.
Competitive Landscape
The entry of multiple generic manufacturers into the dasatinib market has led to significant price competition. As of early 2023, key generic players include Teva, Sandoz, and Mylan, among others. Patent expiration of the branded drug in 2019 prompted increased generic filings and market penetration.
In the US, branded dasatinib (Sprycel) price averages USD 13,000–USD 15,000 per month per patient. Generic versions have driven prices below USD 3,000 per month, with some providers offering discounts or bundled pricing.
Pricing Trends
- Branded Price (Pre-Patents Expiry): USD 13,000–USD 15,000 monthly.
- Generic Price (Post-Entry, 2022-2023): USD 2,500–USD 4,000 monthly.
- Price Erosion Rate: Approximately 70-80% over three years following patent loss, based on comparable TKI launches.
Forecasting Price Trends
Based on current market data:
| Year |
Projected Average Monthly Price (USD) |
Notes |
| 2023 |
USD 2,500–USD 4,000 |
Post-generic market stabilization |
| 2024 |
USD 2,000–USD 3,200 |
Increased competition, possible further discounting |
| 2025+ |
USD 1,500–USD 2,500 |
Potential for further price reductions, especially in Asia-Pacific |
Factors Influencing Future Prices
- Patent Litigation and Certainty: Market entry could be delayed by legal challenges, affecting early pricing.
- Manufacturing Costs: Manufacturing for generics is stabilized around USD 300–USD 500 per month per unit, enabling aggressive pricing.
- Regulatory Changes: Potential biosimilar or interchangeable approval could further reduce prices.
- Healthcare Payer Policies: Cost containment efforts favor lower prices; emphasis on biosimilar adoption impacts pricing.
Regulatory and Policy Environment
The FDA approved multiple ANDAs for dasatinib generics by 2021. The legal landscape remains active, with some patent litigations ongoing. Pricing strategies adapt accordingly, with some manufacturers offering initial discounts to secure market share.
Implications for Stakeholders
- Manufacturers: Entry at USD 1,000–USD 2,000 price points possible, contingent on scale and manufacturing efficiency.
- Healthcare Providers and Payers: Cost reductions improve access, but market segmentation may influence formulary placements.
- Investors: Entry timing, patent challenges, and market share projections are critical for valuation models.
Key Takeaways
- NDC 00074-3641 is a generic dasatinib, with significant market presence following patent expiration.
- The US dominates the market demand, with global demand growing due to aging populations and increasing CML diagnoses.
- Pricing has declined sharply from branded levels; further decreases are anticipated as competition intensifies.
- Price projections suggest a stabilization around USD 1,500–USD 2,500 monthly in subsequent years, influenced by litigation, manufacturing costs, and policy shifts.
- Strategic manufacturers will benefit from cost efficiencies and legal positioning.
FAQs
1. How long before generic prices for dasatinib stabilize?
Market stabilization is expected within 1–2 years after initial entry, assuming no significant legal or regulatory delays.
2. What impact do biosimilars or interchangeable claims have on dasatinib prices?
They could reduce prices by 20-30% further, depending on regulatory approval and market acceptance.
3. How does demand vary between regions?
The US accounts for approximately 40% of global demand; Europe and Asia-Pacific follow, with growth driven by increasing healthcare access and diagnosis rates.
4. What are the main barriers to generic market entry?
Legal patent challenges, manufacturing capacity limitations, and regulatory hurdles are primary obstacles.
5. How does pricing influence patient access?
Lower prices increase accessibility, especially in markets with high out-of-pocket costs or limited insurance coverage.
References
[1] IQVIA, 2022 Market Insights on CML Treatments.
[2] FDA Approved ANDAs for Dasatinib, 2021.
[3] MarketWatch, "Global CML Market Data," 2022.
[4] EvaluatePharma, "TKI Market Trends," 2022.
[5] CMS, "Price Transparency and Payer Policies," 2023.
